TIDMEAH
ECO Animal Health Group plc
Interim Results for the six months ended 30 September 2011
Key features
-- Profit for the period from continuing operations rose to GBP0.44 million
(2010: GBP0.42 million)
-- EBITDA and before share based payments was unchanged at GBP2.2 million
(2010: GBP2.2 million)
-- Basic earnings per share increased over 50 per cent to 0.53 pence
(2010: 0.35 pence)
-- Aivlosin® approval in Canada will have significant impact in next
financial year
-- Preparations for launch of Aivlosin® in USA continue
-- Strong performances in major markets - Latin America, Asia and Middle
East
-- Net cash at period end of GBP8 million after spending GBP2 million on
further drug registration work and the annual dividend
Peter Lawrence, Chairman of ECO Animal Health Group plc, commented:
"The second half has started well. Based on orders booked for delivery in the third quarter, total sales after nine months should be comfortably ahead of last year. The approval forAivlosin® in Canada is another important step in the Company's global marketing plans; sales will commence after the end of the current financial year. ECO's recent additional investment in people and new offices, ahead of imminent further marketing approvals, reflects management's confidence, despite continuing worldwide troubled economies, in the future of the business and its ability to drive growth."
Contacts:
ECO Animal Health Group plc
Peter Lawrence 020 8336 6190
Spiro Financial
Anthony Spiro 020 8336 6196
Cenkos Securities plc (Nominated adviser)
Stephen Keys 020 7397 8926
Elizabeth Bowman 020 7397 8928
ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.
Chairman's statement
I am pleased to report that ECO Animal Health Group has again delivered a good set of results for the six months ended 30 September 2011. Sales and operating profit were comfortably ahead of our budget although below last year's outturn. As expected, some major customers adjusted their delivery schedules to give a stronger second half bias and this was built into our phased budget. The change in the timing of orders is not expected to affect the full year's result, but has distorted the first half performance. The second half of the year is traditionally stronger as the incidence of respiratory disease increases and parasite numbers also rise during the southern hemisphere spring. This trend is already reflected in our results for the first two months of the second half, which are ahead of last year and show that ECO Group's sales are cumulatively ahead of the comparable period in the previous year.
In November, ECO was pleased to report that the Veterinary Drugs Directorate of Health Canada has granted a marketing authorisation for Aivlosin® for pigs. The Health Canada approval is the first in North America for Aivlosin®, ECO's patented macrolide antibiotic, and marks a very important step in the Company's development of its global veterinary product. It further extends the marketing reach of Aivlosin®, which is used for the treatment of respiratory and enteric diseases in pigs and poultry. We anticipate that we will shortly receive a long awaited registration from the Federal Drug Administration, which will allow us to commence sales in the large markets of the USA.
Financial
ECO's earnings before interest, tax, depreciation, amortisation and share based payments (EBITDAS) were GBP2.2 million (2010: GBP2.2 million) and together with sales, were well ahead of our phased budget and confirm the underlying revenue growth trend. Profit from continuing operations rose to GBP0.44 million (2010: GBP0.42 million). Basic earnings per share were 0.53 pence (2010: 0.35 pence), which is an increase of over 50 per cent. Our balance sheet remains strong with almost GBP1.5 million cash generated in the period from our worldwide operations. Net cash remained high at near GBP8 million after investing around GBP2 million in our ongoing drug registration programme and having paid the annual dividend of GBP1 million. Shareholders representing some 22 per cent of holders chose to take the scrip alternative. This enables the Company to conserve cash, which can be redirected to finance our research, development and regulatory affairs which are so important for the future of the business.
The company has recently established a currency hedge position with regard to its exposure to the US dollar and the euro. This action will help to mitigate any real foreign exchange losses, as opposed to accounting regulatory ones, which reflected an uncrystallised currency 'loss' during the period and which can still be reversed if sterling weakens again.
Operations and markets
ECO's sales in US dollars grew by nearly 5 per cent in the period. The relative strength of sterling against the dollar resulted in sterling sales at the Group level being broadly unchanged. Worldwide demand for animal health products for farmed animals is influenced by many factors ranging from levels of economic activity to the influence of outbreaks of disease. This was demonstrated again by the varying level of demand for our products across different territories. Strong double digit growth in US dollars in Latin America, South East Asia, the Middle East and South Africa was offset by a softening in China, although strong orders after the period end have reversed that situation. Japan remains a difficult market and is still affected by local issues resulting from its triple disasters in March. Although trading in Europe has reflected the ongoing economic difficulties, we have appointed additional sales staff in the region to drive sales of both Aivlosin® and Ecomectin®, ECO's range of differentiated generic antiparasitic drugs. The additional (unbudgeted) costs associated with recruitment will, once the economic situation improves, enable the Company to increase its penetration in these high value markets.
After the period end the Veterinary Drugs Directorate (VDD) of Health Canada granted a marketing authorisation for Aivlosin® 625 mg/gwater soluble granules for pigs. This formulation of Aivlosin® will be marketed for the treatment of ileitis (porcine proliferative enteropathy (PPE)), an enteric disease of pigs. Aivlosin® water soluble granules dissolve readily in water providing a simple solution for the accurate and simultaneous treatment of large numbers of animals. Following several years of declining pig numbers in Canada the trend has reversed with producers now looking to consolidate their operations.
Canada and the USA represent more than one third of the world market for ECO's products. We reported in July 2011 that the Aivlosin® regulatory timeline in the USA had been extended by the Federal Drug Administration (FDA), owing to its excessive workload. The FDA was unable to commit to the original review timeline for the final component of the development programme relating to laboratory tests. Although the timeline is not under ECO's control, the Company is making every effort to encourage the FDA to complete the approval of this final component as soon as possible. The joint venture with Pharmgate LLC in the USA, initiated in April 2010, has now been extended by the establishment of a legal entity in Canada. Inevitably, there is an investment cost of set up and administration in the period before sales can commence. This investment, together with expenditure to date, in order to obtain regulatory approval for Aivlosin®, should be rewarded by significant sales and increased Group profits from markets into which so far, we have not been authorised to sell.
In line with our strategic intent of moving closer to the end users in key markets, ECO has established a subsidiary in Mexico which will allow us to benefit from favourable NAFTA free trade agreements and appointed an experienced commercial director to manage the operation.
The development of selected, differentiated generic pet medications of potential major importance to ECO's future continues to progress and remain within our expected timeframes.
Building on the basic research conducted by the Virology Division of the Department of Pathology at the University of Cambridge, funded by the UK Medical Research Council, into the inhibition of viruses by Aivlosin®, ECO has commissioned further research with other institutions and the results will be reported in due course.
Outlook
The second half has started well, boosted by the receipt of orders deferred from the first half. Based on orders booked for delivery in the third quarter, total sales after nine months should be comfortably ahead of last year. The approval forAivlosin® in Canada is another important step in the Company's global marketing plans; sales will commence after the end of the current financial year. ECO's recent additional investment in people and new offices, ahead of imminent further marketing approvals, reflects management's confidence, despite continuing worldwide troubled economies, in the future of the business and its ability to drive growth.
Peter Lawrence
Executive Chairman 9th December 2011
CONSOLIDATED INCOME STATEMENT
FOR THE SIX MONTHS TO
30 SEPTEMBER 2011
Six months Six months Year ended
to to
30.09.11 30.09.10 31.03.11
Notes (unaudited) (unaudited) (audited)
GBP000 GBP000 GBP000
Revenue 3 11,880 12,313 27,078
Cost of sales (7,473) (7,435) (16,365)
Gross Profit 4,407 4,878 10,713
Other operating income 154 87 179
Administrative expenses (2,324) (2,300) (4,610)
Currency (losses) (81) (501) (269)
Amortisation of intangible (1,756) (1,562) (3,240)
assets
Share based payments (103) (103) (304)
Results from operating 297 499 2,469
activities:
Net finance income/(expense) 17 1 (177)
Profit before income tax 314 500 2,292
Income tax 131 (81) (298)
Profit for the period from 445 419 1,994
continuing operations
Attributable to:
Owners 278 183 1,591
Minority interest 167 236 403
445 419 1,994
BASIC EARNINGS PER SHARE 5 0.53p 0.35p 3.07p
FULLY DILUTED EARNINGS 5 0.52p 0.35p 2.96p
PER SHARE
PRE TAX BASIC EARNINGS 4 0.35p 0.46p 3.64p
PER SHARE
Earnings from continuing 2,224 2,241 6,101
activities
before interest, taxation,
depreciation, amortisation,
and share based payments.
CONSOLIDATED STATEMENT OF
COMPREHENSIVE INCOME
FOR THE SIX MONTHS TO
30 SEPTEMBER 2011
Six months Six months Year ended
to to
30.09.11 30.09.10 31.03.11
(unaudited) (unaudited) (audited)
GBP000 GBP000 GBP000
Profit for the period 445 419 1,994
Foreign currency translation 301 (29) 203
differences
Defined benefit pension plan - - 14
- actuarial losses
Revaluation of investment in (51) 79 62
Kiotech International plc
Deferred tax on revaluation 12 (19) (16)
of investment in Kiotech
Revaluation of freehold property - 52 52
Deferred tax on revaluation - (72) (72)
of freehold property
Other comprehensive income 262 11 243
for the period
Total comprehensive income 707 430 2,237
for the period
Attributable to:
Owners 441 232 1,754
Minority interest 266 198 483
707 430 2,237
CONSOLIDATED
STATEMENT
OF
CHANGES
IN
EQUITY
FOR THE
SIX
MONTHS
TO
30
SEPTEMBER
2011
Share Share Other Revaluation Retained Total Minority Total
Capital Premium Reserves Reserves Earnings Interest Equity
Account Account
GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000
At 2,581 45,488 1,142 519 4,569 54,299 1,400 55,699
1 April
2010
Total
comprehensive
income
for the
period
Profit - - - - 1,591 1,591 403 1,994
for
the
period
Other
comprehensive
income
Revaluation - - - 52 - 52 - 52
of
freehold
property
Revaluation - - - 61 - 61 - 61
of
investment
Tax - - - (87) - (87) - (87)
effect
of
revaluations
Foreign - - - - 123 123 80 203
currency
translation
differences
Actuarial - - - - 14 14 - 14
gains
on
pension
scheme
assets
Total - - - 26 1,728 1,754 483 2,237
comprehensive
income
for the
period
Transactions
with
owners
Arising 29 781 - - - 810 - 810
on
issue
of
shares
in the
period
Dividends - - - - (1,191) (1,191) (92) (1,283)
Share - - 304 - - 304 - 304
based
payments
Transfer - - (116) - 116 - - -
to
retained
earnings
on
option
expiry
Total 29 781 188 - (1,075) (77) (92) (169)
transactions
with
owners
At March 2,610 46,269 1,330 545 5,222 55,976 1,791 57,767
2011
Total
comprehensive
income
for
the
period:
Profit - - - - 278 278 167 445
for
the
period
Other
comprehensive
income
Revaluation - - - - - - - -
of
freehold
property
Revaluation - - - (51) - (51) - (51)
of
investments
Tax - - - 12 - 12 - 12
effect
of
revaluations
Foreign - - - - 202 202 99 301
currency
translation
differences
Total - - - (39) 480 441 266 707
comprehensive
income
for the
period
Transactions
with
owners
Arising 11 395 - - - 406 - 406
on
issue
of
shares
in the
period
Dividends - - - - (1,567) (1,567) (389) (1,956)
Share - - 103 - - 103 - 103
based
payments
Transfer - - (96) - 96 - - -
to
retained
earnings
on
option
expiry
Total 11 395 7 - (1,471) (1,058) (389) (1,447)
transactions
with
owners
At 2,621 46,664 1,337 506 4,231 55,359 1,668 57,027
September
2011
Prior
interim
period
At 2,581 45,488 1,142 519 4,569 54,299 1,400 55,699
1 April
2010
Total
comprehensive
income
for
the
period:
Profit - - - - 183 183 236 419
for
the
period
Other
comprehensive
income
Revaluation - - - 52 - 52 - 52
of
freehold
property
Revaluation - - - 79 - 79 - 79
of
investments
Tax - - - (91) - (91) - (91)
effect
of
revaluations
Foreign - - - - 9 9 (38) (29)
currency
translation
differences
Total - - - 40 192 232 198 430
comprehensive
income
for the
period
Transactions
with
owners
Arising 24 690 - - - 714 - 714
on
issue
of
shares
in the
period
Dividends - - - - (1,191) (1,191) - (1,191)
Share - - 103 - - 103 - 103
based
payments
Total 24 690 103 - (1,191) (374) - (374)
transactions
with
owners
At 2,605 46,178 1,245 559 3,570 54,157 1,598 55,755
30
September
2010
CONSOLIDATED
STATEMENT
OF FINANCIAL
POSITION
As at As at As at
30.09.11 30.09.10 31.03.11
Notes (unaudited) (unaudited) (audited)
GBP000 GBP000 GBP000
ASSETS
Non current
assets
Property, 9 1,392 1,151 1,277
plant
and equipment
Goodwill and 8 38,734 37,968 38,637
other
intangibles
Investments 93 385 351
40,219 39,504 40,265
Current assets
Inventories 4,947 3,491 4,804
Trade and 8,660 7,029 9,643
other
receivables
Income 303 340 356
tax
recoverable
Other taxes 196 233 95
and social
security
Cash and cash 11,312 10,970 9,471
equivalents
25,418 22,063 24,369
Total assets 65,637 61,567 64,634
Current
liabilities
Trade and (4,370) (3,352) (5,795)
other
payables
Short term (3,414) (1,138) (53)
borrowings
Income tax (13) (36) (78)
Other taxes (110) (176) (77)
and social
security
Dividends (29) (397) (32)
(7,936) (5,099) (6,035)
Total assets 57,701 56,468 58,599
less current
liabilities
Non
current
liabilities
Deferred tax (674) (713) (832)
57,027 55,755 57,767
Equity
Capital and
reserves
Called up 2,621 2,605 2,610
share
capital
Share premium 46,664 46,178 46,269
Revaluation 506 559 545
reserve
Other reserves 1,337 1,245 1,330
Retained 4,231 3,570 5,222
earnings
55,359 54,157 55,976
Minority 1,668 1,598 1,791
interest
57,027 55,755 57,767
CONSOLIDATED
STATEMENT
OF CASH FLOWS
Six months to Six months to Year ended
30.09.11 30.09.10 31.03.11
(unaudited) (unaudited) (audited)
GBP000 GBP000 GBP000
Profit before 314 500 2,292
tax
Adjustment
for:
Net (17) (1) 178
finance
(income)/costs
Depreciation 69 77 88
of plant
and equipment
Amortisation 1,755 1,562 3,240
of (46) - -
intangible
assets
Profit on
disposal
of investment
Pension - - (59)
payments
Pension - - 2
operating
costs
Share based 103 103 303
payments
Operating cash 2,178 2,241 6,044
flow
before
movement
in working
capital
Change (143) 2,206 893
in inventories
Change 882 1,967 (421)
in receivables
Change in (1,392) (185) 2,159
payables
Cash generated 1,525 6,229 8,675
from
operations
Interest paid (16) (39) (54)
Income tax (27) (87) (156)
paid
Net cash 1,482 6,103 8,465
inflow
from
operating
activities
Cash flows
from
investing
activities
Purchase of (165) (88) (151)
property, 253 - -
plant
and equipment
Sale
of investments
Cost (1,851) (1,986) (4,270)
of acquiring
drug
registrations
Interest 64 40 73
received
Net cash (used (1,699) (2,034) (4,348)
in) Investing
activities
Cash flows
from
financing
activities
Issue of 63 208 306
shares
Dividends paid (1,616) (319) (776)
Net cash (used (1,553) (111) (470)
in)/generated
from financing
activities
Net (1,770) 3,958 3,647
(decrease)/increase
in
cash and cash
equivalents
Foreign 250 (29) (132)
exchange
movements
Cash and cash 9,418 5,903 5,903
equivalents
at
the beginning
of
the period
Cash and cash 7,898 9,832 9,418
equivalents
at the end of
the period
NOTES TO THE PRELIMINARY RESULTS FOR THE SIX MONTHS TO 30SEPTEMBER 2010
1. Basis of preparation
The financial information for the period to 30 September 2011 does not constitute statutory accounts as defined by Section 435 of the Companies Act 2006. It has been prepared in accordance with the accounting policies set out in, and is consistent with, the audited financial statements for the twelve months to 31 March 2011.
The Group applies revised IAS 1 "Presentation of Financial Statements (2007)", which became effective as of 1 January 2009. As a result, the Group presents all non owner changes in equity in consolidated statements of comprehensive income and all owner changes in equity in consolidated changes in equity.
2. Statement of compliance
The interim financial statements do not include all of the information required for full annual financial statements and do not comply with all of the disclosure requirements in IAS 34 "Interim Financial Reporting". Accordingly, whilst the interim statements have been prepared in accordance with IFRS, they cannot be construed as being in full compliance with IFRS and should be read in conjunction with the consolidated financial statements of the Group for the year ended 31 March 2011.
3. Revenue is derived from the Group's animal pharmaceutical businesses.
4. Principal risks and uncertainties were set out on pages 55-57 of the notes to the consolidated financial statements for the year ended 31 March 2011. The key exposures are to foreign currency exchange rates, potential delays in obtaining market authorisations and single sources of supply for some raw materials and have remained unchanged since the year end.
5. Earnings per share
Six months to Six months to Year ended
30.09.11 30.09.10 31.03.11
(unaudited) (unaudited) (audited)
Weighted average number of 52,221 51,773 51,873
shares in issue (000's)
Fully diluted weighted 53,376 51,773 53,733
average number
of shares in issue (000's)
Profit attributable 277,573 183,274 1,590,000
to equity
holders of the
Company (GBP's)
Basic earnings per 0.53 0.35 3.07
share (pence)
Fully diluted earnings 0.52 0.35 2.96
per share (pence)
6.Dividends
Six months to Six months to Year ended
30.09.11 30.09.10 31.03.11
(unaudited) (unaudited) (audited)
GBP000 GBP000 GBP000
Final dividend in
respect of the
year ended 31 March 2011(2010)
52,253,172 (2010: 51,777,768) 1,567 1,191 1,191
shares 389 - 93
at 3.0p (2010:2.3p) per share
Dividend paid by subsidiary
to minority interests
1,956 1,191 1,284
7. Related party transactions
At the balance sheet date, ECO Animal Health Group plc owed P A Lawrence, a director of ECO Animal Health Group plc, and members of his family a balance amounting to GBP478,199 (30 September 2010: GBP4,864). During the period the Group provided management services to Kiotech International plc and C-Corp Limited, companies in which P A Lawrence is a director and holds equity interests. Fees charged were: Kiotech International plc GBP13,000 (2010: GBP13,000) and C-Corp Limited GBP25,287 (2010: GBP22,450). During the period, the Group also acquired a freehold property from C-Corp Limited at an arm's basis for total consideration of GBP155,000.
During the period the Group made sales to Zhejiang ECO Biok Animal Health Products Limited at an arm's length basis to the value of GBP1,096,382 (Six months to 30 September 2010: GBP577,551). At the end of this period there was an intercompany balance owing from this company of GBP778,226 (30 September 2010: GBP563,339).
The Group also made sales on an arm's length basis to ECO Animal Health do Brasil Comercio de Productos Veterinarios Ltda to the value of GBP1,095,032 (Six months to 30 September 2010: GBP1,329,221). At the end of the period there was an intercompany balance of GBP1,515,949 (30 September 2010: GBP1,762,146).
The Group also made sales on an arm's length basis to ECOpharma Inc to the value of GBP85,220 (30 September 2010: GBP621,279). At the end of the period there was an intercompany balance of GBP486,361 (30 September 2010: GBP420,296).
Since the last three of these companies are subsidiaries of ECO Animal Health Group plc, these transactions and balances have been eliminated on consolidation.
During the period ECO Animal Health Limited and ECO Animal Health Group plc received dividends of GBP404,442 (2010: GBPnil) from Zhejiang ECO Animal Health Products Limited. This amount has also been eliminated on consolidation.
8. Intangible non current assets
Distribution Development
Goodwill Rights Costs Total
GBP000 GBP000 GBP000 GBP000
Cost
Cost at 1 April 2010 17,930 1,035 31,127 50,092
Additions - - 1,986 1,986
Cost at 30 September 2010 17,930 1,035 33,113 52,078
Additions - - 2,284 2,284
Foreign exchange - - 63 63
movements
Cost at 31 March 2011 17,930 1,035 35,460 54,425
Additions - - 1,851 1,851
Cost at 30 September 2011 17,930 1,035 37,311 56,276
Amortisation
Amortisation at - 316 12,233 12,549
1 April 2010
Charge for the period - 28 1,534 1,562
Amortisation at 30 - 344 13,767 14,111
September 2010
Charge for the period - 27 1,651 1,678
Amortisation at - 371 15,418 15,789
31 March 2011
Charge for the period - 28 1,727 1,755
Foreign exchange movement - - (2) (2)
Amortisation at 30 - 399 17,143 17,542
September 2011
Net book value at 30 17,930 636 20,168 38,734
September 2011
Net book value at 17,930 664 20,042 38,636
31 March 2011
Net book value at 30 17,930 691 19,346 37,967
September 2010
Net book value at 17,930 719 18,894 37,543
1 April 2010
9. Property, plant and equipment
Fixtures Motor
Freehold Plant and fittings & Vehicles
property machinery equipment Total
GBP000 GBP000 GBP000 GBP000 GBP000
Cost
Cost at 1 April 2010 650 762 535 - 1,947
Additions - 51 37 - 88
Cost at 30 September 650 813 572 - 2,035
2010
Reclassifications - - (42) 42 -
Additions - 42 22 - 64
Foreign exchange - 280 - - 280
movements
Cost at 1April 2011 650 1,135 552 42 2,379
Additions 157 3 5 - 165
Foreign exchange
movements - 56 - - 56
Cost at 30 September 807 1,194 557 42 2,600
2011
Depreciation
Depreciation at 52 359 448 - 859
1 April 2010
Revaluation in (52) - - - (52)
the period
Charge for 5 56 16 - 77
the period
Depreciation at 30 5 415 464 - 884
September 2010
Charge for 4 (25) 26 8 13
the period
Foreign exchange - 203 - 2 205
movements
Depreciation at 9 593 490 10 1,102
1 April 2011
Charge for 5 41 17 6 69
the period
Foreign exchange - 37 - - 37
movements
Depreciation at 30 14 671 507 16 1,208
September 2011
Net book value at 30 793 523 50 26 1,392
September 2011
Net book value at 641 542 62 32 1,277
1 April 2011
Net book value at 30 645 398 108 - 1,151
September 2010
Net book value at 598 403 87 - 1,088
1 April 2010
10.Share Premium Cancellation
On 5th October 2011, just after the period end, ECO Animal Health Group plc obtained an order to confirm the cancellation of GBP10 million of its Share Premium Account and the transfer of this sum to its Distributable Reserves in accordance with the resolution passed by shareholders at the Annual General Meeting held on 2nd September 2011. The order was registered at Companies house on 7th October 2011. This will permit the Board much greater flexibility to determine its future distribution policy.
11. Cashflow
The cash generated from operations was GBP4.7m less than in the same period last year. This was because the inventory figure at September 2010 was unusually very low and the Company has since been building inventory to cover the expected increase in sales. The Company also reduced its trade payables by GBP1.4m in the period which is largely a function of the timing of payments to suppliers between one period and the next.
Group cash flow was also affected by an increase in dividends paid in the period compared to last year and was the result of the increase in the dividend declared as well as a decline in the take up of the scrip alternative. Finally, the minority interest's share of our Chinese subsidiary's dividend paid in the period resulted in a further GBP389,000 of cash outflow to the Group.
12. This financial information was approved by the board on 9 December 2011.
Copies of this interim report are being sent to all of the Company's shareholders. Further copies can be obtained from the Company's registered office at 78 Coombe Road, New Malden, Surrey KT3 4QS.
DIRECTORS AND OFFICERS PETER LAWRENCE (CHAIRMAN)
MARC LOOMES (CHIEF EXECUTIVE)
KEVIN STOCKDALE (FINANCE DIRECTOR)
JULIA TROUSE (EXECUTIVE DIRECTOR AND COMPANY SECRETARY)
BRETT CLEMO (EXECUTIVE DIRECTOR)
DAVID DANSON (NON-EXECUTIVE DIRECTOR)
JULIA HENDERSON (NON-EXECUTIVE DIRECTOR)
REGISTERED OFFICE 78 COOMBE ROAD, NEW MALDEN, SURREY KT3 4QS
TEL: 020-8336-2900 FAX: 020-8336-0909
COMPANY NUMBER 01818170
|
